Hidradenitis Suppurativa Market - Top Companies and Manufacturers

In the News

March 26, 2024: F. Hoffmann-La Roche Ltd., declared the U.S. Food and Drug Administration (FDA) acceptance of the cobas® Malaria test for utilization on the cobas® 6800/8800 Systems. This accepted test can help healthcare professionals in limiting the possible risks of patient infection from imbued blood materials. The cobas Malaria test gives a highly sensitive and particular solution to assist confirm that polluted blood units are eliminated from the blood supply.

March 05, 2024: F. Hoffmann-La Roche Ltd. and Alnylam declared that the Phase II KARDIA-2 study [NCT05103332] of zilebesiran, an examinational RNAi therapeutic in growth for the therapy of hypertension (high blood pressure) - the foremost cause of cardiovascular disease globally - met its basic endpoint. People with mild to intermediate hypertension cured with zilebesiran added to standard-of-care hypertension medicines experienced a clinically and numerically substantial limitation in systolic blood pressure at month three.